evolocumab + alirocumab

Evolocumab and alirocumab are both PCSK9 inhibitors used to treat high cholesterol. They are fully human monoclonal antibodies that bind to and inhibit PCSK9, an enzyme that normally marks LDL receptors for degradation. By blocking PCSK9, these drugs allow more LDL receptors to remain on liver cell surfaces, enhancing the removal of LDL cholesterol from the bloodstream. Both are administered via subcutaneous injection and are primarily indicated for patients with extremely high cholesterol levels, particularly those with familial hypercholesterolemia or established cardiovascular disease who haven't responded adequately to other cholesterol-lowering treatments.

Brand names

Repatha + Praluent